Abstract Number: 486 • 2015 ACR/ARHP Annual Meeting
Persistence Among Rheumatoid Arthritis Patients Initiating Intravenous or Subcutaneous Anti-Tumor Necrosis Factor Therapy in a Large US Registry Cohort
Background/Purpose: The objective of this analysis was to examine persistence with intravenous (IV) and subcutaneous (SC) anti-TNF therapies among rheumatoid arthritis (RA) patients (pts) within…Abstract Number: 572 • 2015 ACR/ARHP Annual Meeting
Predictors of Long-Term Retention of Infliximab and Golimumab in Rheumatoid Arthritis: An Analysis from a Prospective, Observational Registry
Background/Purpose: Previous studies have shown differences in treatment retention between anti-TNF agents. Furthermore, although inconsistent, data from the literature suggest that some factors (e.g. concomitant…Abstract Number: 1292 • 2015 ACR/ARHP Annual Meeting
What Is the Effect of TNF Inhibitors on Employment Status in Rheumatoid Arthritis Patients and What Are the Predictors of Progression to Unemployment?
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, progressive inflammatory disease which has been associated with an increased incidence of disability and unemployment over time. The…Abstract Number: 1315 • 2015 ACR/ARHP Annual Meeting
Detecting Subtle Changes in Bone Structure Following Three-Month Anti-TNF Theraphy Using High-Resolution Peripheral Quantitative Computed Tomography
Background/Purpose: Radiographs have been traditionally used to detect bone erosions and joint space narrowing (JSN) in rheumatoid arthritis (RA), but they are not sensitive to…Abstract Number: 2779 • 2015 ACR/ARHP Annual Meeting
Better Drug Survival of Non-TNFi Compared to TNFi Biologics after Non-TNFi Failure in RA Patients: A Single Center Experience
Background/Purpose: There are sparse data in the literature regarding the drug survival of TNFi vs. non-TNFi biologics in rheumatoid arthritis (RA) patients who have already…Abstract Number: 2483 • 2014 ACR/ARHP Annual Meeting
Treatment Adjustment Strategy after Achieving Remission or Low Disease Activity in Rheumatoid Arthritis : A Systematic Review and Meta-Analysis
Conflict of interest : NONE.Background/Purpose Attaining remission or at least low-disease activity (LDA) is a goal achieved in a significant proportion of rheumatoid arthritis (RA) patients…Abstract Number: 2422 • 2014 ACR/ARHP Annual Meeting
A Tailored Approach to Reduce Dose of TNF Inhibitors Is Equally Effective, but Substantially Less Costly Than Standard Dosing in Patients with Rheumatoid Arthritis over One and Two Years: A Prospective Cohort Study
Background/Purpose: To compare effectiveness and costs of standard versus individually tailored reduced doses of TNF inhibitors (TNFi) in patients with Rheumatoid Arthritis (RA) after achieving…Abstract Number: 2400 • 2014 ACR/ARHP Annual Meeting
Comparing a Tapering Strategy to the Standard Dosing Regimen of TNF Inhibitors in Patients with Rheumatoid Arthritis in Remission or with Low Disease Activity
Background/Purpose: There is a growing interest about optimization of biological therapies but for now no strong evidence is available to support a tapering strategy in…Abstract Number: 397 • 2014 ACR/ARHP Annual Meeting
Th9 Lymphocytes in Rheumatoid Arthritis
Background/Purpose Th9 cells are IL-9-secreting Th lymphocytes that are involved in the immunological responses underlying parasitic infections and allergic diseases. In the case of autoimmune…Abstract Number: 2325 • 2013 ACR/ARHP Annual Meeting
Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized, Placebo-Controlled Trial Of Golimumab In Patients With Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy
Background/Purpose: GO-AFTER was the first multicenter, randomized, placebo (PBO)-controlled trial of the safety/efficacy of an anti-TNFα agent, GLM, in pts with active RA despite prior…Abstract Number: 1414 • 2013 ACR/ARHP Annual Meeting
Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized Placebo-Controlled Trial Of Golimumab In Patients With Active Rheumatoid Arthritis Despite Prior Treatment With Methotrexate
Background/Purpose: The safety and efficacy of subcutaneous golimumab (GLM)+/-MTX has been evaluated through 2yrs in a phase 3 trial (GO-FORWARD) of pts with active rheumatoid…Abstract Number: 1416 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Subcutaneous Golimumab In Chinese Patients With Active Rheumatoid Arthritis Despite MTX Therapy: Results From a Randomized, Placebo-Controlled, Phase 3 Trial
Background/Purpose: Assess safety and efficacy of GLM+MTX over 1yr in a multicenter, randomized, placebo (PBO)-controlled study of Chinese pts with active RA despite MTX therapy.…Abstract Number: 1350 • 2013 ACR/ARHP Annual Meeting
Factors Influencing Selection Of Biologic Therapy and Comparative Effectiveness In Patient Reported Outcomes Among Patients With Rheumatoid Arthritis
Background/Purpose: Treatment of rheumatoid arthritis (RA) with biologics is increasingly common. A better understanding of factors that influence the selection of RA therapies and comparative effectiveness…Abstract Number: 1331 • 2013 ACR/ARHP Annual Meeting
Mathematical Model To Predict The Early Responders In a Monocentric Cohort Of Patients With Rheumatoid Arthritis Treated By Anti TNF-Alpha
Background/Purpose: In the last few year the introduction of biological agents has radically changed the clinical outcome of patients with Rheumatoid Arthritis (RA). However, no…Abstract Number: 874 • 2013 ACR/ARHP Annual Meeting
Sustained and Consistent Clinical Benefit With Intravenous Golimumab Therapy In Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results Through 1-Year Of a Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial
Background/Purpose: To report on sustainability and consistency of ACR component scores with intravenous (IV) golimumab (GLM) 2mg/kg+methotrexate (MTX) through wk52 in pts with active rheumatoid…